Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
The endocrinological actions of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex (goserelin) in premenopausal women with advanced breast cancer are reviewed. LHRH analogues are an interesting addition to the currently available treatments for hormone-sensitive breast cancer in premenopausal women. Their modest side effects and ease of administration are in contrast to the risks and morbidity of surgical endocrine therapy.
Nicholson
R I
RI
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Cardiff, UK.
Walker
K J
KJ
Walker
R F
RF
Read
G F
GF
Turkes
A
A
Robertson
J F
JF
Blamey
R W
RW
D000328:Adult; D000735:Androstenedione / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004970:Estrone / Q000097:blood; D005260:Female; D017273:Goserelin; D006801:Humans; D008875:Middle Aged; D013739:Testosterone / Q000097:blood
D017273:Goserelin; D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D002064:Buserelin